Background
==========

Systemic androgen-deprivation therapy by orchiectomy or agonists of gonadotropic releasing hormone are routinely used to treat men with metastatic prostate cancer to reduce tumor burden and pain. This therapy is based on the dependency of prostate cells for androgens to grow and survive. The inability of androgen-deprivation therapy to completely and effectively eliminate all metastatic prostate cancer cell populations is manifested by a predictable and inevitable relapse, referred to as castration-recurrent prostate cancer (CRPC). CRPC is the end stage of the disease and fatal to the patient within 16-18 months of onset.

The mechanisms underlying progression to CRPC are unknown. However, there are several models to explain its development. One such model indicates the involvement of the androgen signaling pathway\[[@B1]-[@B4]\]. Key to this pathway is the androgen receptor (AR) which is a steroid hormone receptor and transcription factor. Mechanisms of progression to CRPC that involve or utilize the androgen signaling pathway include: hypersensitivity due to *AR*gene amplification \[[@B5],[@B6]\]; changes in AR co-regulators such as nuclear receptor coactivators (*NCOA1*and *NCOA2*) \[[@B7],[@B8]\]; intraprostatic *de novo*synthesis of androgen\[[@B9]\] or metabolism of AR ligands from residual adrenal androgens\[[@B10],[@B11]\]; AR promiscuity of ligand specificity due to mutations\[[@B12]\]; and ligand-independent activation of AR by growth factors \[protein kinase A (PKA), interleukin 6 (IL6), and epidermal growth factor (EGF)\]\[[@B13]-[@B15]\]. Activation of the AR can be determined by assaying for the expression of target genes such as prostate-specific antigen (PSA)\[[@B16]\]. Other models of CRPC include the neuroendocrine differentiation \[[@B17]\], the stem cell model \[[@B18]\] and the imbalance between cell growth and cell death \[[@B3]\]. It is conceivable that these models may not mutual exclusive. For example altered AR activity may impact cell survival and proliferation.

Here, we describe long serial analysis of gene expression (LongSAGE) libraries\[[@B19],[@B20]\] made from RNA sampled from biological replicates of the *in vivo*LNCaP Hollow Fiber model of prostate cancer as it progresses to the castration-recurrent stage. Gene expression signatures that were consistent among the replicate libraries were applied to the current models of CRPC.

Methods
=======

*In vivo*LNCaP Hollow Fiber model
---------------------------------

The LNCaP Hollow Fiber model of prostate cancer was performed as described previously\[[@B21]-[@B23]\]. All animal experiments were performed according to a protocol approved by the Committee on Animal Care of the University of British Columbia. Serum PSA levels were determined by enzymatic immunoassay kit (Abbott Laboratories, Abbott Park, IL, USA). Fibers were removed on three separate occasions representing different stages of hormonal progression that were androgen-sensitive (AS), responsive to androgen-deprivation (RAD), and castration-recurrent (CR). Samples were retrieved immediately prior to castration (AS), as well as 10 (RAD) and 72 days (CR) post-surgical castration.

RNA sample generation, processing, and quality control
------------------------------------------------------

Total RNA was isolated immediately from cells harvested from the *in vivo*Hollow Fiber model using TRIZOL Reagent (Invitrogen) following the manufacturer\'s instructions. Genomic DNA was removed from RNA samples with DNaseI (Invitrogen). RNA quality and quantity were assessed by the Agilent 2100 Bioanalyzer (Agilent Technologies, Mississauga, ON, Canada) and RNA 6000 Nano LabChip kit (Caliper Technologies, Hopkinton, MA, USA).

Quantitative real-time polymerase chain reaction
------------------------------------------------

Oligo-d(T)-primed total RNAs (0.5 μg per sample) were reverse-transcribed with SuperScript III (Invitrogen Life Technologies, Carlsbad, CA, USA). An appropriate dilution of cDNA and gene-specific primers were combined with SYBR Green Supermix (Invitrogen) and amplified in ABI 7900 real-time PCR machine (Applied Biosystems, Foster City, CA, USA). All qPCR reactions were performed in triplicate. The threshold cycle number (Ct) and expression values with standard deviations were calculated in Excel. Primer sequences for real-time PCRs are: *KLK3*, F\': 5\'-CCAAGTTCATGCTGTGTGCT-3\' and R:\' 5\'-CCCATGACGTGATACCTTGA-3\'; glyceraldehyde-3-phosphate (*GAPDH*), F\': 5\'-CTGACTTCAACAGCGACACC-3\' and R:\' 5\'-TGCTGTAGCCAAATTCGTTG-3\'). Real-time amplification was performed with initial denaturation at 95°C for 2 min, followed by 40 cycles of two-step amplification (95°C for 15 sec, 55°C for 30 sec).

LongSAGE library production and sequencing
------------------------------------------

RNA from the hollow fibers of three mice (biological replicates) representing different stages of prostate cancer progression (AS, RAD, and CR) were used to make a total of nine LongSAGE libraries. LongSAGE libraries were constructed and sequenced at the Genome Sciences Centre, British Columbia Cancer Agency. Five micrograms of starting total RNA was used in conjunction with the Invitrogen I-SAGE Long kit and protocol with alterations \[[@B24]\]. Raw LongSAGE data are available at Gene Expression Omnibus \[[@B25]\] as series accession number GSE18402. Individual sample accession numbers are as follows: S1885, GSM458902; S1886, GSM458903; S1887, GSM458904; S1888, GSM458905; S1889, GSM458906; S1890, GSM458907; S1891, GSM458908; S1892, GSM458909; and S1893, GSM458910.

Gene expression analysis
------------------------

LongSAGE expression data was analyzed with DiscoverySpace 4.01 software \[[@B26]\]. Sequence data were filtered for bad tags (tags with one N-base call) and linker-derived tags (artifact tags). Only LongSAGE tags with a sequence quality factor (QF) greater than 95% were included in analysis. The phylogenetic tree was constructed with a distance metric of 1-r (where \"r\" equals the Pearson correlation coefficient). Correlations were computed (including tag counts of zero) using the Regress program of the Stat package written by Ron Perlman, and the tree was optimized using the Fitch program\[[@B27]\] in the Phylip package\[[@B28]\]. Graphics were produced from the tree files using the program TreeView\[[@B29]\]. Tag clustering analysis was performed using the Poisson distribution-based K-means clustering algorithm. The K-means algorithm clusters tags based on count into \'K\' partitions, with the minimum intracluster variance. PoissonC was developed specifically for the analysis of SAGE data \[[@B30]\]. The java implementation of the algorithm was kindly provided by Dr. Li Cai (Rutgers University, NJ, USA). An optimal value for K (K = 10) was determined \[[@B31]\].

Principle component analysis
----------------------------

Principle component analysis was performed using GeneSpring™ software version 7.2 (Silicon Genetics, CA). Affymetrix datasets of clinical prostate cancer and normal tissue were downloaded from Gene Expression Omnibus \[[@B25]\] (accession numbers: GDS1439 and GDS1390) and analyzed in GeneSpring™. Of the 96 novel CR-associated genes, 76 genes had corresponding Affymetrix probe sets. These probe sets were applied as the gene signature in this analysis. Principle component (PC) scores were calculated according to the standard correlation between each condition vector and each principle component vector.

Results
=======

LongSAGE library and tag clustering
-----------------------------------

RNA isolated from the LNCaP Hollow Fiber model was obtained from at least three different mice (13N, 15N, and 13R; biological replicates) at three stages of cancer progression that were androgen-sensitive (AS), responsive to androgen-deprivation (RAD), and castration-recurrent (CR). To confirm that the samples represented unique disease-states, we determined the levels of *KLK3*mRNA, a biomarker that correlates with progression, using quantitative real time-polymerase chain reaction (qRT-PCR). As expected, *KLK3*mRNA levels dropped in the stage of cancer progression that was RAD versus AS (58%, 49%, and 37%), and rose in the stage of cancer progression that was CR versus RAD (229%, 349%, and 264%) for mice 13R, 15N, and 13N, respectively (Additional file [1](#S1){ref-type="supplementary-material"}). Therefore, we constructed nine LongSAGE libraries, one for each stage and replicate.

LongSAGE libraries were sequenced to 310,072 - 339,864 tags each, with a combined total of 2,931,124 tags, and filtered to leave only useful tags for analysis (Table [1](#T1){ref-type="table"}). First, bad tags were removed because they contain at least one N-base call in the LongSAGE tag sequence. The sequencing of the LongSAGE libraries was base called using PHRED software. Tag sequence-quality factor (QF) and probability was calculated to ascertain which tags contain erroneous base-calls. The second line of filtering removed LongSAGE tags with probabilities less than 0.95 (QF \< 95%). Linkers were introduced into SAGE libraries as known sequences utilized to amplify ditags prior to concatenation. At a low frequency, linkers ligate to themselves creating linker-derived tags (LDTs). These LDTs do not represent transcripts and were removed from the LongSAGE libraries. A total of 2,305,589 useful tags represented by 263,197 tag types remained after filtering. Data analysis was carried out on this filtered data.

###### 

Composition of LongSAGE libraries

  Library                   S1885      S1886      S1887     S1888     S1889       S1890     S1891     S1892     S1893
  ------------------------- ---------- ---------- --------- --------- ----------- --------- --------- --------- ---------
  Mouse-Condition           13N-AS\*   13N-RAD†   13N-CR‡   15N-AS    15N-RAD     15N-CR    13R-AS    13R-RAD   13R-CR
  Unfiltered Total Tags     310,516    318,102    339,864   338,210   310,072     326,870   337,546   314,440   335,504
  No. of Bad Tags           955        1,010      1,083     1,097     983         737       900       744       832
                                                                                                                
  Minus Bad Tags                                                                                                
                                                                                                                
  Total Tags                309,561    317,092    338,781   337,113   309,089     326,133   336,646   313,696   334,672
  Tag Types                 79,201     96,973     99,730    81,850    84,499      88,249    79,859    91,438    90,675
  No. of Duplicate Ditags   19,761     12,220     12,678    21,973    17,471      12,836    24,552    12,786    13,127
  \% of Duplicate Ditags    6.38       3.85       3.74      6.52      5.65        3.94      7.29      4.08      3.92
  Average QF§ of Tags       0.85       0.88       0.87      0.86      0.89        0.88      0.88      0.80      0.87
  No. of Tags QF \< 0.95    63,057     62,872     71,576    68,993    54,627      54,470    68,981    101,215   69,647
                                                                                                                
  Q ≥ 0.95                                                                                                      
                                                                                                                
  Total Tags                246,504    254,220    267,205   268,120   254,462     271,663   267,665   212,481   265,025
  Tag Types                 52,033     67,542     66,748    52,606    59,374      64,985    53,715    54,682    64,837
  Total Tags Combined                                                 2,307,345                                 
  Tag Types Combined                                                  263,199                                   
  No. of LDTs II Type I     124        72         174       179       84          186       164       118       301
  No. of LDTs Type II       19         9          54        56        33          40        60        24        59
                                                                                                                
  Minus LDTs                                                                                                    
                                                                                                                
  Total Tags                246,361    254,139    266,977   267,885   254,345     271,437   267,441   212,339   264,665
  Tag Types                 52,031     67,540     66,746    52,604    59,372      64,983    53,713    54,680    64,835
  Total Tags Combined                                                 2,305,589                                 
  Tag Types Combined                                                  263,197                                   

\* AS, Androgen-sensitive

† RAD, Responsive to androgen-deprivation

‡ CR, Castration-recurrent

§ QF, Quality Factor

II LDTs, Linker-derived tags

The LongSAGE libraries were hierarchically clustered and displayed as a phylogenetic tree. In most cases, LongSAGE libraries made from the same disease stage (AS, RAD, or CR) clustered together more closely than LongSAGE libraries made from the same biological replicate (mice 13N, 15N, or 13R; Figure [1](#F1){ref-type="fig"}). This suggests the captured transcriptomes were representative of disease stage with minimal influence from biological variation.

![**Clustering of the nine LongSAGE libraries in a hierarchical tree**. The tree was generated using a Pearson correlation-based hierarchical clustering method and visualized with TreeView. LongSAGE libraries constructed from similar stages of prostate cancer progression (AS, androgen-sensitive; RAD, responsive to androgen-deprivation; and CR, castration-recurrent) cluster together. 13N, 15N, and 13R indicate the identity of each animal.](1755-8794-3-43-1){#F1}

Identification of groups of genes that behave similarly during progression of prostate cancer was conducted through K-means clustering of tags using the PoissonC algorithm \[[@B30]\]. For each biological replicate (mice 13N, 15N, or 13R), all tag types were clustered that had a combined count greater than ten in the three libraries representing disease stages (AS, RAD, and CR) and mapped unambiguously sense to a transcript in reference sequence (RefSeq; February 28^th^, 2008) \[[@B32]\] using DiscoverySpace4 software \[[@B33]\]. By plotting within cluster dispersion (i.e., intracluster variance) against a range of K (number of clusters; Additional file [1](#S1){ref-type="supplementary-material"}, Figure S2), we determined that ten clusters best embodied the expression patterns present in each biological replicate. This was decided based on the inflection point in the graph (Additional file [1](#S1){ref-type="supplementary-material"}, Figure S2), showing that after reaching K = 10, increasing the number of K did not substantially reduce the within cluster dispersion. K-means clustering was performed over 100 iterations, so that tags would be placed in clusters that best represent their expression trend. The most common clusters for each tag are displayed (Figure [2](#F2){ref-type="fig"}). In only three instances, there were similar clusters in just two of the three biological replicates. Consequently, consistent changes in gene expression during progression were represented in 11 patterns. Differences among expression patterns for each biological replicate may be explained by biological variation, the probability of sampling a given LongSAGE tag, and/or imperfections in K-means clustering (e.g, variance may not be a good measure of cluster scatter).

![**K-means clustering of tag types with similar expression trends**. PoissonC with K = 10 (where K = number of clusters) was conducted over 100 iterations separately for each biological replicate (mice 13N, 15N, and 13R) and the results from the iterations were combined into consensus clusters shown here. Plotted on the x-axes are the long serial analysis of gene expression (LongSAGE) libraries representing different stages of prostate progression: AS, androgen-sensitive; RAD, responsive to androgen-deprivation; and CR, castration-recurrent. Plotted on the y-axes are the relative expression levels of each tag type, represented as a percentage of the total tag count (for a particular tag type) in all three LongSAGE libraries. Different colors represent different tag types. Each of the ten clusters for each biological replicate are labeled as such. \'No equivalent\' indicates that a similar expression trend was not observed in the indicated biological replicate. Eleven expression patterns are evident in total and are labeled on the left. K-means clusters were amalgamated into five major expression trends: group 1, up during progression; group 2, down during progression; group 3, peak in the RAD stage; group 4, constant during progression; and group 5, valley in RAD stage.](1755-8794-3-43-2){#F2}

Gene ontology enrichment analysis
---------------------------------

We conducted Gene Ontology (GO) \[[@B34]\] enrichment analysis using Expression Analysis Systematic Explorer (EASE) \[[@B35]\] software to determine whether specific GO annotations were over-represented in the K-means clusters. Enrichment was defined by the EASE score (p-value ≤ 0.05) generated during comparison to all the other clusters in the biological replicate. This analysis was done for each biological replicate (3 mice: 13N, 15N, or 13R).

To enable visual differences between the 11 expression trends, the clusters were amalgamated into five major trends: group 1, up during progression; group 2, down during progression; group 3, peak in the RAD stage; group 4, constant during progression; and group 5, valley in RAD stage (Figure [2](#F2){ref-type="fig"}). To be consistent, the GO enrichment data was combined into five major trends which resulted in redundancy in GO terms. To simplify the GO enrichment data, similar terms were pooled into representative categories. Categorical gene ontology enrichments of the five major expression trends are shown in Figure [3](#F3){ref-type="fig"}. These data indicate that steroid binding, heat shock protein activity, de-phosphorylation activity, and glycolysis all decreased in the stage that was RAD, but increased again in the stage that was CR. Interestingly, steroid hormone receptor activity continues to increase throughout progression. Both of these expression trends were observed for genes with GO terms for transcription factor activity or secretion. The GO categories for genes with kinase activity and signal transduction displayed expression trends with peaks and valleys at the stage that was RAD. The levels of expression of genes involved in cell adhesion rose in the stage that was RAD, but dropped again in the stage that was CR.

![**Gene Ontology enrichments of the five major expression trends**. Plotted on the x-axis are Gene Ontology (GO) categories enriched in one or more of the five major expression trends. On the z-axis the five major expression trends correspond to Figure 2 and are: group 1, up during progression; group 2, down during progression; group 3, peak in the RAD stage; group 4, constant during progression; and group 5, valley in RAD stage. The y-axis displays the number of biological replicates (number of mice: 1, 2, or 3) exhibiting enrichment. The latter allows one to gauge the magnitude of the GO enrichment and confidence.](1755-8794-3-43-3){#F3}

Altogether, genes with functional categories that were enriched in expression trends may be consistent with the AR signaling pathway playing a role in progression of prostate cancer to castration-recurrence (Figure [3](#F3){ref-type="fig"}). For example, GO terms steroid binding, steroid hormone receptor activity, heat shock protein activity, chaperone activity, and kinase activity could represent the cytoplasmic events of AR signaling. GO terms transcription factor activity, regulation of transcription, transcription corepression activity, and transcription co-activator activity could represent the nuclear events of AR signaling. AR-mediated gene transcription may result in splicing and protein translation, to regulate general cellular processes such as proliferation (and related nucleotide synthesis, DNA replication, oxidative phosphorylation, oxioreductase activity, and glycolysis), secretion, and differentiation.

It should be noted, however, that both positive and negative regulators were represented in the GO enriched categories (Figure [3](#F3){ref-type="fig"}). Therefore, a more detailed analysis was required to determine if the pathways represented by the GO-enriched categories were promoted or inhibited during progression to CRPC. Moreover, many of the GO enrichments that were consistent with changes in the AR signaling pathway were generic, and could be applied to the other models of CRPC.

Consistent differential gene expression associated with progression of prostate cancer
--------------------------------------------------------------------------------------

Pair-wise comparisons were made between LongSAGE libraries representing the transcriptomes of different stages (AS, RAD, and CR) of prostate cancer progression from the same biological replicate (3 mice: 13N, 15N, or 13R). Among all three biological replicates, the number of consistent statistically significant differentially expressed tag types were determined using the Audic and Claverie test statistic \[[@B36]\] at p ≤ 0.05, p ≤ 0.01, and p ≤ 0.001 (Table [2](#T2){ref-type="table"}). The tags represented in Table [2](#T2){ref-type="table"} were included only if the associated expression trend was common among all three biological replicates. The Audic and Claverie statistical method is well-suited for LongSAGE data, because the method takes into account the sizes of the libraries and tag counts. Tag types were counted multiple times if they were over, or under-represented in more than one comparison. The number of tag types differentially expressed decreased by 57% as the stringency of the p-value increased from p ≤ 0.05 to 0.001.

###### 

Number of tag types consistently and significantly differentially expressed among all three biological replicates and between conditions\*

  Comparison     Change        p ≤ 0.001    p ≤ 0.01     p ≤ 0.05
  -------------- ------------- ------------ ------------ ------------
  AS† vs. RAD‡   Up in RAD     21           44           83
                 Down in RAD   [68]{.ul}    [105]{.ul}   [149]{.ul}
                 Total         89           149          232
                                                         
  RAD vs. CR§    Up in CR      24           45           89
                 Down in CR    [46]{.ul}    [59]{.ul}    [104]{.ul}
                 Total         70           104          193
                                                         
  AS vs. CR      Up in CR      111          167          294
                 Down in CR    [127]{.ul}   [168]{.ul}   [256]{.ul}
                 Total         238          335          550

\* Statistics according to the Audic and Claverie test statistic

† AS, Androgen-sensitive

‡ RAD, Responsive to androgen-deprivation

§ CR, Castration-recurrent

Tag types consistently differentially expressed in pair-wise comparisons were mapped to RefSeq (March 4th, 2008). Tags that mapped anti-sense to genes, or mapped ambiguously to more than one gene were not included in the functional analysis. GO, Kyoto Encyclopedia of Genes and Genomes (KEGG; v45.0) \[[@B37]\] pathway, and SwissProt (v13.0) \[[@B38]\] keyword annotation enrichment analyses were conducted using EASE (v1.21; March 11^th^, 2008) and FatiGO (v3; March 11^th^, 2008) \[[@B39]\] (Table [3](#T3){ref-type="table"}). This functional analysis revealed that the expression of genes involved in signaling increased during progression, but the expression of genes involved in protein synthesis decreased during progression. Cell communication increased in the stage that was RAD but leveled off in the stage that was CR. Carbohydrate, lipid and amino acid synthesis was steady in the RAD stage but increased in the CR stage. Lastly, glycolysis decreased in the RAD stage, but was re-expressed in the CR stage (Table [3](#T3){ref-type="table"}).

###### 

Top five enrichments of functional categories of tags consistently and significantly differentially expressed among all three biological replicates and between stages of prostate cancer\*

  Top 5 GO † categories                   P-value ‡   Top 5 KEGG § annotations                                  P-value II   Top 5 SwissProt annotations            P-value II
  --------------------------------------- ----------- --------------------------------------------------------- ------------ -------------------------------------- ------------
  AS vs. RAD: Up in RAD¶                                                                                                                                            
                                                                                                                                                                    
  Cell communication                      2.E-02      Stilbene, coumarine and lignin biosynthesis               1.E-02       Antioxidant                            7.E-04
  Extracellular                           2.E-02      Butanoate metabolism                                      2.E-02       Cell adhesion                          5.E-03
  Extracellular matrix                    2.E-02      2,4-Dichlorobenzoate degradation                          2.E-02       Signal                                 6.E-03
  Synaptic vesicle transport              3.E-02      Cell adhesion molecules (CAMs)                            2.E-02       Fertilization                          7.E-03
  Synapse                                 4.E-02      Alkaloid biosynthesis II                                  5.E-02       Amyotrophic lateral sclerosis          7.E-03
                                                                                                                                                                    
  AS vs. RAD: Down in RAD                                                                                                                                           
                                                                                                                                                                    
  Glycolysis                              3.E-05      Glycolysis/Gluconeogenesis                                3.E-05       Glycolysis                             3.E-07
  Glucose catabolism                      1.E-04      Ribosome                                                  2.E-03       Pyrrolidone carboxylic acid            8.E-05
  Hexose catabolism                       1.E-04      Carbon fixation                                           3.E-03       Pyridoxal phosphate                    2.E-04
  Hexose metabolism                       2.E-04      Fructose and mannose metabolism                           2.E-02       Gluconeogenesis                        3.E-04
  Monosaccharide catabolism               2.E-04      Urea cycle and metabolism of amino groups                 3.E-02       Coiled coil                            5.E-03
                                                                                                                                                                    
  RAD vs. CR: Up in CR                                                                                                                                              
                                                                                                                                                                    
  Acid phosphatase activity               4.E-02      gamma-Hexachlorocyclohexane degradation                   5.E-03       Lyase                                  2.E-03
  Lyase activity\*\*                      7.E-02      Glycolysis/Gluconeogenesis                                3.E-02       Immune response                        5.E-03
  Carbohydrate metabolism\*\*             9.E-02      O-Glycan biosynthesis                                     5.E-02       Signal                                 6.E-03
  Extracellular\*\*                       1.E-01      Ether lipid metabolism\*\*                                6.E-02       Glycolysis                             7.E-03
  Catabolism\*\*                          1.E-01      Phenylalanine, tyrosine and tryptophan biosynthesis\*\*   6.E-02       Progressive external ophthalmoplegia   1.E-02
                                                                                                                                                                    
  RAD vs. CR: Down in CR                                                                                                                                            
                                                                                                                                                                    
  Cytosolic ribosome                      2.E-09      Ribosome                                                  2.E-11       Ribosomal protein                      6.E-10
  Large ribosomal subunit                 1.E-07      Urea cycle and metabolism of amino groups                 1.E-02       Ribonucleoprotein                      3.E-08
  Cytosol                                 2.E-07      Arginine and proline metabolism                           4.E-02       Acetylation                            1.E-05
  Cytosolic large ribosomal subunit       2.E-07      Type II diabetes mellitus\*\*                             1.E-01       Elongation factor                      1.E-03
  Protein biosynthesis                    2.E-07      Phenylalanine metabolism\*\*                              1.E-01       rRNA-binding                           2.E-03
                                                                                                                                                                    
  AS vs. CR: Up in CR                                                                                                                                               
                                                                                                                                                                    
  Synapse                                 4.E-03      Butanoate metabolism                                      2.E-03       Glycoprotein                           2.E-03
  Extracellular                           5.E-03      Ascorbate and aldarate metabolism                         2.E-02       Vitamin C                              7.E-03
  Transition metal ion binding            7.E-03      Phenylalanine metabolism                                  2.E-02       Lipoprotein                            1.E-02
  Metal ion binding                       2.E-02      Linoleic acid metabolism                                  2.E-02       Signal                                 1.E-02
  Extracellular matrix                    2.E-02      gamma-Hexachlorocyclohexane degradation                   2.E-02       Heparin-binding                        1.E-02
                                                                                                                                                                    
  AS vs. CR: Down in CR                                                                                                                                             
                                                                                                                                                                    
  Cytosolic ribosome                      4.E-12      Ribosome                                                  2.E-09       Acetylation                            2.E-07
  Biosynthesis                            7.E-11      Carbon fixation                                           9.E-04       Ribosomal protein                      1.E-06
  Macromolecule biosynthesis              2.E-10      Glycolysis/Gluconeogenesis                                3.E-03       Glycolysis                             7.E-05
  Protein biosynthesis                    1.E-08      Glycosphingolipid biosynthesis - lactoseries              4.E-02       Ribonucleoprotein                      8.E-05
  Eukaryotic 43 S preinitiation complex   2.E-08      Glutamate metabolism\*\*                                  8.E-02       Protein biosynthesis                   1.E-04

\* Statistics according to the Audic and Claverie test statistic (p ≤ 0.05)

† GO, Gene Ontology

‡ P-value represents the raw EASE (Expression Analysis Systematic Explorer) score

§ KEGG, Kyoto Encyclopedia of Genes and Genomes

II Unadjusted p-value was computed using FatiGO

¶ AS, androgen-sensitive; RAD, responsive to androgen-deprivation; CR, castration-recurrent

\*\* Not statistically significant (p \> 0.05)

Tag types differentially expressed between the RAD and CR stages of prostate cancer were of particular interest (Table [4](#T4){ref-type="table"}). This is because these tags potentially represent markers for CRPC and/or are involved in the mechanisms of progression to CRPC. These 193 tag types (Table [2](#T2){ref-type="table"}) were mapped to databases RefSeq (July 9^th^, 2007), Mammalian Gene Collection (MGC; July 9^th^, 2007) \[[@B40]\], or Ensembl Transcript or genome (v45.36d) \[[@B41]\]. Only 135 of the 193 tag types were relevant (Table [4](#T4){ref-type="table"}) with 48 tag types that mapped ambiguously to more than one location in the *Homo Sapiens*transcriptome/genome, and another 10 tag types that mapped to *Mus musculus*transcriptome/genome. *Mus musculus*mappings may be an indication of minor contamination of the *in vivo*LNCaP Hollow Fiber model samples with host (mouse) RNA. These 135 tag types represented 114 candidate genes with 7 tag types that did not map to the genome, 5 tag types that mapped to unannotated genomic locations, and 9 genes that were associated with more than one tag type. Table [4](#T4){ref-type="table"} shows the LongSAGE tag sequences and tag counts per million tags in all nine libraries. Tags were sorted into groups based on expression trends. These trends are visually represented in Additional file [1](#S1){ref-type="supplementary-material"}, Figure S3. Mapping information was provided where available.

###### 

Gene expression trends of LongSAGE tags that consistently and significantly altered expression in CR prostate cancer\*

                      13N    15N     13R                                                                 
  ------------------- ------ ------- ------ ------ ------- ------ ------ ------ ------ --- ------------- -----------------
  TCTAGAGAACACTGTGC   12†    79      382    7      67      136    7      52     200    A   *ACPP*‡‡      NM_001099
  TAATTTTTCTAAGGTGT   101    311     648    119    397     895    120    546    918    A   *C1ORF80*     ENSG00000186063
  TGAGAGAGGCCAGAACA   8      39      150    4      39      144    7      33     95     A   N/A           Genomic
  CTCATAAGGAAAGGTTA   637    952     1680   653    1170    1540   688    1620   1930   A   *RNF208*      BC090061
  GATTTCTATTTGTTTTT   89     169     446    116    208     339    86     311    555    A   *SERINC5*     ENSG00000164300
  GTTGGGAAGACGTCACC   426    571     742    273    417     741    262    363    495    A   *STEAP1*      NM_012449
  GAGGATCACTTGAGGCC   191    299     449    134    189     589    187    203    314    B   *AMACR*‡‡     BC009471
  TTGTTGATTGAAAATTT   219    197     528    273    197     479    232    391    586    B   *AMD1*‡‡      NM_001634
  TTTGCTTTTGTTTTGTT   53     16      169    34     51      129    7      28     72     B   *AQP3*        NM_004925
  GTTCGACTGCCCACCAG   45     28      101    52     47      122    34     42     106    B   *ASAH1*††     NM_177924
  TAATAAACAGGTTTTTA   426    232     648    332    315     700    138    250    491    B   *ASAH1*‡‡     NM_177924
  TCACAGCTGTGAAGATC   85     110     277    161    71      258    310    438    945    B   *BTG1*        NM_001731
  AAAAGAGAAAGCACTTT   24     75      199    19     35      85     15     90     552    B   *CAMK2N1*     NM_018584
  CAAAACAGGCAGCTGGT   4      71      169    15     83      162    37     75     268    B   *CAMK2N1*††   NM_018584
  AGGAGGAAGAATGGACT   33     59      187    49     67      247    26     42     223    B   *CCNH*        NM_001239
  TTTTAAAAATATAAAAT   89     83      243    97     130     269    64     170    382    B   *COMT*        NM_000754
  GAATGAAATAAAAAATA   134    252     626    209    240     357    116    160    272    B   *DHRS7*       NM_016029
  AAAGTGCATCCTTTCCC   118    146     318    153    220     394    288    231    646    B   *FGFRL1*      NM_001004356
  AAACTGAATAAGGAGAA   24     51      236    19     51      438    19     146    283    B   *GALNT3*      NM_004482
  TTTAAGGAAACATTTGA   4      4       75     4      4       81     0      0      57     B   *GALNT3*††    NM_004482
  CCAACCGTGCTTGTACT   191    327     521    202    279     534    172    363    510    B   *GLO1*        NM_006708
  GAGGGCCGGTGACATCT   300    378     1170   321    476     1230   254    447    1030   B   *H2AFJ*       NM_177925
  TATCATTATTTTTACAA   57     63      161    67     63      181    75     94     181    B   *HSD17B4*     NM_000414
  AATGCACTTATGTTTGC   16     8       64     22     16      77     19     28     98     B   N/A           No map
  ACCTTCGCAGGGGAGAG   0      0       19     0      4       41     0      5      34     B   N/A           Genomic
  ATAACCTGAAAGGAAAG   0      16      56     7      4       74     0      28     87     B   N/A           No map
  GTGATGTGCACCTGTTG   0      0       38     4      0       30     0      5      45     B   N/A           No map
  GTTTGGAGGTACTAAAG   20     43      94     34     87      169    34     90     234    B   N/A           Genomic
  TTTTCAAAAATTGGAAA   0      35      180    7      4       59     0      19     61     B   N/A           No map
  GAAAAATTTAAAGCTAA   394    397     569    433    598     788    853    862    1060   B   *NGFRAP1*     NM_206917
  CAAATTCAGGGAGCACA   0      4       139    4      16      228    0      14     136    B   *OPRK1*       NM_000912
  CTATTGTCTGAACTTGA   0      8       109    0      12      70     0      9      227    B   *OR51E2*      BC020768
  ATGCTAATTATGGCAAT   4      12      75     4      8       74     0      5      57     B   *PCGEM1*      NR_002769
  CAGAAAGCATCCCTCAC   4      43      195    0      16      111    7      33     264    B   *PLA2G2A*‡‡   NM_000300
  TAATTTTAGTGCTTTGA   16     75      154    37     59      162    4      57     132    B   *PTGFR*       NM_000959
  TTGTTTGTAAATAGAAT   0      12      94     0      4       162    0      14     72     B   *QKI*         NM_206853
  TAAACACTGTAAAATCC   0      4       75     0      4       66     0      0      42     B   *QKI*††       NM_206853
  AGCAGATCAGGACACTT   20     35      112    15     16      140    15     42     98     B   *S100A10*     NM_002966
  CTGCCATAACTTAGATT   37     55      161    93     63      192    56     99     264    B   *SBDS*        NM_016038
  TGGCTGAGTTTATTTTT   20     24      79     41     8       96     4      42     147    B   *SFRS2B*      NM_032102
  GAAGATTAATGAGGGAA   126    142     277    108    130     402    101    188    325    B   *SNX3*        NM_003795
  ATGGTACTAAATGTTTT   16     47      124    37     28      88     11     19     76     B   *SPIRE1*      NM_020148
  TATATATTAAGTAGCCG   45     39      101    45     75      133    41     75     178    B   *STEAP2*‡‡    NM_152999
  CAACAATATATGCTTTA   24     32      82     75     32      136    26     99     212    B   *STEAP2*††    NM_152999
  TTTCATTGCCTGAATAA   24     43      150    34     59      114    22     61     178    B   *TACC1*‡‡     NM_006283
  TTGGCCAGTCTGCTTTC   8      16      67     4      4       77     0      5      38     B   *TMEM30A*     ENSG00000112697
  ATATCACTTCTTCTAGA   12     4       26     7      4       26     0      52     140    C   *ADAM2*‡‡     NM_001464
  ATGTGTGTTGTATTTTA   812    338     768    1010   315     1020   269    702    865    C   *BNIP3*       NM_004052
  CCACGTTCCACAGTTGC   601    291     599    530    346     700    381    339    559    C   *ENO2*        NM_001975
  CTGATCTGTGTTTCCTC   16     0       26     0      4       41     19     0      34     C   *HLA-B*       BC013187
  AGCCCTACAAACAACTA   382    441     596    508    456     619    400    631    1010   C   *MT-ND3*      ENSG00000198840
  ATATTTTCTTTGTGGAA   20     12      90     7      0       48     4      0      23     C   N/A           No map
  CAAGCATCCCCGTTCCA   2400   2130    2440   2730   1720    2250   1020   2010   2340   C   N/A           ENSG00000211459
  GTTGTAAAATAAACTTT   118    83      172    228    87      247    112    203    378    C   N/A           Genoic
  TTGGATTTCCAAAGCAG   12     0       19     0      0       33     0      0      26     C   N/A           Genomic
  TCTTTTAGCCAATTCAG   138    181     420    381    326     468    389    334    457    C   *NKX3-1*††    NM_006167
  TGATTGCCCTTTCATAT   73     39      86     86     39      107    108    99     181    C   *P4HA1*       NM_000917
  GTAACAAGCTCTGGTAT   28     16      56     49     24      66     11     19     72     C   *PJA2*        NM_014819
  ACAGTGCTTGCATCCTA   85     75      139    108    98      203    101    118    196    C   *PPP2CB*      NM_004156
  AGGCGAGATCAATCCCT   57     39      101    37     24      122    131    66     268    C   *PSMA7*       NM_002792
  TATTTTGTATTTATTTT   73     59      180    93     51      111    22     94     253    C   *SLC25A4*     NM_001151
  TTATGGATCTCTCTGCG   1050   1260    1820   1140   1300    2260   1990   1010   1530   C   *SPON2*       NM_012445
  CAGTTCTCTGTGAAATC   767    515     1060   855    503     914    467    608    1200   C   *TMEM66*      NM_016127
  AAATAAATAATGGAGGA   138    59      255    82     118     284    165    90     159    C   *TRPM8*       NM_024080
  ATGTTTAATTTTGCACA   61     87      154    157    59      195    217    85     344    C   *WDR45L*      NM_019613
  GGGCCCCAAAGCACTGC   861    543     1180   1020   657     1590   1240   739    937    E   *C19orf48*    NM_199249
  TCCCCGTGGCTGTGGGG   1670   1390    2290   1740   1410    1720   3370   970    1180   E   *DHCR24*‡‡    BC004375
  GCATCTGTTTACATTTA   487    201     345    444    208     468    684    226    423    E   *ELOVL5*      NM_021814
  GAAATTAGGGAAGCCTT   317    153     311    310    181     542    359    193    298    E   *ENDOD1*      XM_290546
  GGATGGGGATGAAGTAA   2780   1160    4780   2950   1350    3620   2930   1230   1890   E   *KLK3*‡‡      NM_001648
  TGAAAAGCTTAATAAAT   313    142     322    474    181     332    273    179    314    E   *TPD52*       NM_001025252
  GTTGTGGTTAATCTGGT   1770   634     1270   1800   806     1190   2480   659    960    F   *B2M*         NM_004048
  GAAACAAGATGAAATTC   4380   1170    2260   5300   1110    2720   3750   2220   2830   F   *PGK1*        NM_000291
  AGCACCTCCAGCTGTAC   2150   1130    648    2060   1560    939    1560   1200   722    G   *EEF2*        NM_001961
  GCACAAGAAGATTAAAA   536    228     124    762    425     195    838    278    174    G   *GAS5*        NR_002578
  CCGCTGCGTGAGGGCAG   451    169     56     429    197     44     516    94     0      G   *HES6*        NM_018645
  GCCCAGGTCACCCACCC   585    55      4      519    79      7      456    66     0      G   *LOC644844*   XM_927939
  ATGCAGCCATATGGAAG   2650   386     82     2470   216     129    1210   259    98     G   *ODC1*        NM_002539
  CGCTGGTTCCAGCAGAA   1420   811     479    1250   959     553    800    589    374    G   *RPL11*       NM_000975
  AAGACAGTGGCTGGCGG   2650   1730    1220   2460   1860    1350   2120   1630   1270   G   *RPL37A*‡‡    NM_000998
  TTCTTGTGGCGCTTCTC   925    543     217    1030   708     273    1130   419    306    G   *RPS11*††     NM_001015
  GGTGAGACACTCCAGTA   463    252     165    485    346     192    363    245    159    G   *SLC25A6*     NM_001636
  AGGTTTTGCCTCATTCC   982    515     281    1200   491     243    688    782    166    H   *ABHD2*       NM_007011
  TGAAGGAGCCGTCTCCA   317    272     187    392    295     199    366    259    140    H   *ATP5G2*      NM_001002031
  CTCAGCAGATCCAAGAG   191    185     67     254    232     66     142    231    79     H   *C17orf45*    NM_152350
  CTGTGACACAGCTTGCC   308    397     172    209    307     125    295    226    110    H   *CCT2*        NM_006431
  TCTGCACCTCCGCTTGC   495    606     277    426    570     276    366    471    204    H   *EEF1A2*      NM_001958
  GCCCAAGGACCCCCTGC   114    114     38     138    98      41     101    42     4      H   *FLNA*‡‡      NM_001456
  TTATGGGATCTCAACGA   564    425     180    642    452     317    430    490    253    H   *GNB2L1*      NM_006098
  TCTGCAAAGGAGAAGTC   81     102     38     105    87      26     165    80     30     H   *HMGB2*       NM_002129
  CTTGTGAACTGCACAAC   268    228     124    231    177     103    273    160    57     H   *HN1*         NM_016185
  TCTGAAGTTTGCCCCAG   313    291     150    254    299     155    187    226    72     H   *MAOA*        NM_000240
  TTAATTGATAGAATAAA   483    350     199    422    287     103    273    235    83     H   *MAOA*        NM_000240
  GGCAGCCAGAGCTCCAA   1200   1260    420    1050   672     350    681    819    23     H   *MARCKSL1*    NM_023009
  CCCTGCCTTGTCCCTCT   353    240     112    310    263     107    176    193    102    H   *MDK*         NM_001012334
  CTGTGGATGTGTCCCCC   649    476     169    459    389     214    430    297    117    H   N/A           No map
  CTCCTCACCTGTATTTT   1120   771     262    1220   979     313    666    730    261    H   *RPL13A*‡‡    NM_012423
  GCAGCCATCCGCAGGGC   1980   1770    809    2300   1730    928    2150   1570   1020   H   *RPL28*       NM_000991
  GGATTTGGCCTTTTTGA   3470   2070    1370   4170   2910    1540   2800   2870   2500   H   *RPLP2*‡‡     NM_001004
  TCTGTACACCTGTCCCC   2320   1670    850    1930   1880    825    2130   1490   1120   H   *RPS11*       NM_001015
  GCTTTTAAGGATACCGG   1510   1050    626    1860   1120    593    1550   1550   960    H   *RPS20*‡‡     NM_001023
  CCCCAGCCAGTCCCCAC   921    519     281    788    664     357    1100   438    291    H   *RPS3*        NM_001005
  CCCCCAATGCTGAGGCC   89     138     26     90     94      30     90     80     30     H   *SF3A2*       NM_007165
  GCCGCCATCTCCGAGAG   195    102     30     168    118     55     172    108    30     H   *TKT*         NM_001064
  GGCCATCTCTTCCTCAG   349    307     202    317    346     173    277    254    121    H   *YWHAQ*       NM_006826
  AGGCTGTGTTCCTCCGT   16     39      11     34     67      22     26     38     8      I   *ACY1*        NM_000666
  TGCCTCTGCGGGGCAGG   446    649     427    399    664     424    501    462    317    I   *CD151*       NM_004357
  GGCACAGTAAAGGTGGC   175    216     142    332    350     173    456    316    204    I   *CUEDC2*      NM_024040
  TCACACAGTGCCTGTCG   49     71      7      30     47      15     34     66     4      I   *CXCR7*       NM_001047841
  TGTGAGGGAAGCTGCTT   53     87      15     67     102     52     52     90     42     I   *FKBP10*      BC016467
  TGCTTTGCTTCATTCTG   28     63      26     22     79      26     49     118    61     I   *GRB10*       NM_005311
  GTACTGTATGCTTGCCA   170    212     82     134    153     88     123    188    113    I   *KPNB1*‡‡     NM_002265
  GTGGCAGTGGCCAGTTG   106    193     97     123    173     96     94     137    76     I   N/A           ENSG00000138744
  GGGGAGCCCCGGGCCCG   61     63      26     30     51      18     34     57     0      I   *NAT14*       NM_020378
  TGTTCAGGACCCTCCCT   28     67      26     60     63      26     60     28     0      I   *NELF*        NM_015537
  TTTTCCTGGGGATCCTC   41     130     15     37     87      33     56     104    45     I   PCOTH         NM_001014442
  GAAACCCGGTAGTCTAG   41     75      4      37     75      26     52     151    30     I   *PLCB4*       NM_000933
  GTCTGACCCCAGGCCCC   126    205     82     119    193     103    157    179    38     I   *PPP2R1A*     NM_014225
  GGCCCGAGTTACTTTTC   231    150     75     161    232     136    142    160    45     I   *RPL35A*††    NM_000996
  GTTCGTGCCAAATTCCG   881    696     390    1100   712     523    497    782    461    I   *RPL35A*‡‡    NM_000996
  TTACCATATCAAGCTGA   877    535     311    1130   598     405    636    791    578    I   *RPL39*‡‡     NM_001000
  GCTGCAGCACAAGCGGC   268    244     127    45     216     125    157    71     11     I   *RPS18*††     NM_022551
  AGCTCTTGGAGGCACCA   203    319     206    142    421     243    269    259    162    I   *SELENBP1*    NM_003944
  TGCTGGTGTGTAAGGGG   69     102     45     82     87      37     105    75     30     I   *SH3BP5L*     NM_030645
  GAGAGTAACAGGCCTGC   191    150     71     112    181     111    108    165    64     I   *SYNC1*       NM_030786
  CTGAAAACCACTCAAAC   394    508     225    306    547     236    310    381    200    I   *TFPI*        NM_006287
  TAAAAAAGGTTTCATCC   183    248     127    86     130     66     142    268    87     I   *TFPI*        NM_006287
  CTCCCTCCTCTCCTACC   28     32      4      30     39      7      71     24     0      I   *TK1*         NM_003258
  CATTTTCTAATTTTGTG   544    744     236    407    771     181    288    664    185    J   N/A           No map
  TGATTTCACTTCCACTC   3480   5260    3910   3700   6110    3590   3040   5960   2600   K   *MT-CO3*      ENSG00000198938
  TTTCTGTCTGGGGAAGG   130    236     82     123    201     111    101    188    113    K   *PIK3CD*      NM_005026
  GCCGCTACTTCAGGAGC   256    370     199    224    330     169    142    316    38     K   *RAMP1*       NM_005855
  ATGGTTACACTTTTGGT   93     161     94     75     208     118    60     226    95     K   *UTX*         NM_021140
  CACTACTCACCAGACGC   2820   3900    3020   2740   4290    2440   2620   3120   1260   K   *VPS13B*††    ENSG00000132549
  CTAAGACTTCACCAGTC   7120   11000   9730   6390   10900   8330   3610   8870   7850   L   N/A           ENSG00000210082

\* Statistics according to the Audic and Claverie test statistic (p ≤ 0.05)

† Tag count per 1 million = (observed tag count/total tags in the library) × 1,000,000

‡ Trends are visually represented from A to P in Additional file [1](#S1){ref-type="supplementary-material"}, Figure S3. In addition to p-value considerations, significantly different trends were also required to display uniform directions of change in each biological replicate.

§ AS, Androgen-sensitive

II RAD, Responsive to androgen-deprivation

¶ CR, Castration-recurrent

\*\* Human Genome Nomenclature Committee (HGNC)-approved gene names were used when possible. Non-HGNC-approved gene names were not italicized.

†† Tag maps antisense to gene

‡‡ Gene is known to display this expression trend in castration-recurrence

§§ Accession numbers were displayed following the priority (where available): RefSeq \> Mammalian Gene Collection \> Ensembl Gene. If the tag mapped to more than one transcript variant of the same gene, the accession number of the lowest numerical transcript variant was displayed.

We cross-referenced these 114 candidate genes with 28 papers that report global gene expression analyses on tissue samples from men with \'castration-recurrent\', \'androgen independent,\' \'hormone refractory,\' \'androgen-ablation resistant,\' \'relapsed,\' or \'recurrent\' prostate cancer, or animal models of castration-recurrence \[[@B42]-[@B69]\]. The candidate genes were identified with HUGO Gene Nomenclature Committee (HGNC) approved gene names, aliases, descriptions, and accession numbers. The gene expression trends of 18 genes of 114 genes were previously associated with CRPC. These genes were: *ACPP, ADAM2, AMACR, AMD1, ASAH1, DHCR24, FLNA, KLK3, KPNB1, PLA2G2A, RPL13A, RPL35A, RPL37A, RPL39, RPLP2, RPS20, STEAP2*, and *TACC*(Table [4](#T4){ref-type="table"}). To our knowledge, the gene expression trends of the remaining 96 genes have never before been associated with CRPC (Tables [4](#T4){ref-type="table"} &[5](#T5){ref-type="table"}).

A literature search helped to gauge the potential of these 96 genes to be novel biomarkers or therapeutic targets of CRPC. The results of this literature search are presented in Table [5](#T5){ref-type="table"}. We found 31 genes that encode for protein products that are known, or predicted, to be plasma membrane bound or secreted extracellularly (Bioinformatic Harvester). These genes were: *ABHD2, AQP3, B2 M, C19orf48, CD151, CXCR7, DHRS7, ELOVL5, ENDOD1, ENO2, FGFRL1, GNB2L1, GRB10, HLA-B, MARCKSL1, MDK, NAT14, NELF, OPRK1, OR51E2, PLCB4, PTGFR, RAMP1, S100A10, SPON2, STEAP1, TFPI, TMEM30A, TMEM66, TRPM8*, and *VPS13B*. Secretion of a protein could facilitate detection of the putative biomarkers in blood, urine, or biopsy sample. Twenty-one of the candidate genes are known to alter their levels of expression in response to androgen. These genes were: *ABHD2, B2 M, BTG1, C19orf48, CAMK2N1, CXCR7, EEF1A2, ELOVL5, ENDOD1, HSD17B4, MAOA, MDK, NKX3-1, ODC1, P4HA1, PCGEM1, PGK1, SELENBP1, TMEM66, TPD52*, and *TRPM8*\[[@B9],[@B22],[@B70]-[@B81]\]. Genes regulated by androgen may be helpful in determining the activation status of AR in CRPC. Enriched expression of a protein in prostate tissue could be indicative of whether a tumor is of prostatic origin. Eight of these 96 genes are known to be over-represented in prostate tissue \[[@B75],[@B82]-[@B85]\]. These genes were: *ELOVL5, NKX3-1, PCGEM1, PCOTH, RAMP1, SPON2, STEAP1*, and *TPD52*. Twenty-six genes (*ABHD2, BNIP3, EEF1A2, ELOVL5, GALNT3, GLO1*, *HSD17B4, MARCKSL1, MDK, NGFRAP1, ODC1, OR51E2, PCGEM1*, PCOTH, *PGK1, PP2CB, PSMA7, RAMP1, RPS18, SELENBP1, SLC25A4, SLC25A6, SPON2, STEAP1, TPD52*, and *TRPM8*) have known associations to prostate cancer \[[@B57],[@B82],[@B86]-[@B102]\]. Six genes (*C1orf80, CAMK2N1, GLO1, MAOA, PGK1*, and *SNX3*) have been linked to high Gleason grade \[[@B58],[@B103],[@B104]\], and twelve genes (*B2 M, CAMK2N1, CD151, COMT, GALNT3, GLO1, ODC1, PCGEM1*, PCOTH, *SBDS, TMEM30A*, and *TPD52*) have been implicated in the \'progression\' of prostate cancer \[[@B58],[@B82]\], and 15 more genes (*CD151, CXCR7, DHRS7, GNB2L1, HES6, HN1, NKX3-1, PGK1, PIK3CD, RPL11, RPS11, SF3A2, TK1, TPD52*, and *VPS13B*) in the metastasis of prostate cancer \[[@B105],[@B106]\].

###### 

Characteristics of genes with novel association to castration-recurrence *in vivo*

                                     Associated with                       Associated with                                            
  ----------------- ------ ---- ---- ----------------- ---- ---- ---- ---- ----------------- ------ ---- ---- ---- ---- ---- -------- ----
  *ABHD2*           PM     Y↑   \-   Y↑                \-   \-   \-   \-   *NKX3-1*          \-     Y↑   Y    \-   \-   \-   Y        \-
  *ACY1*            \-     \-   \-   \-                \-   \-   \-   \-   *ODC1*            \-     Y↑   \-   Y↑   \-   Y↓   \-       Y↑
  *AQP3*            PM     \-   \-   \-                \-   \-   \-   \-   *OPRK1*           PM     \-   \-   \-   \-   \-   \-       \-
  *ATP5G2*          \-     \-   \-   \-                \-   \-   \-   \-   *OR51E2*          PM     \-   \-   Y↑   \-   \-   \-       \-
  *B2M*             S&PM   Y↑   \-   \-                \-   Y↑   \-   Y↓   *P4HA1*           \-     Y    \-   \-   \-   \-   \-       \-
  *BNIP3*           \-     \-   \-   Y↓                \-   \-   \-   \-   *PCGEM1*          \-     Y↑   Y    Y↑   \-   Y↑   \-       \-
  *BTG1*            \-     Y↓   \-   \-                \-   \-   \-   \-   PCOTH             \-     \-   Y    Y↑   \-   Y↑   \-       \-
  *C17orf45*        \-     \-   \-   \-                \-   \-   \-   \-   *PGK1*            \-     Y↑   \-   Y↓   Y↑   \-   Y ↑↓§§   \-
  C19orf48          S      Y↑   \-   \-                \-   \-   \-   \-   PIK3CD            \-     \-   \-   \-   \-   \-   Y↑       Y↑
  C1orf80           \-     \-   \-   \-                Y↑   \-   \-   \-   PJA2              \-     \-   \-   \-   \-   \-   \-       \-
  CAMK2N1           \-     Y↓   \-   \-                Y↑   Y↑   \-   \-   PLCB4             PM     \-   \-   \-   \-   \-   \-       \-
  CCNH              \-     \-   \-   \-                \-   \-   \-   \-   PPP2CB            \-     \-   \-   Y↓   \-   \-   \-       \-
  CCT2              \-     \-   \-   \-                \-   \-   \-   \-   PPP2R1A           \-     \-   \-   \-   \-   \-   \-       \-
  CD151             PM     \-   \-   \-                \-   Y↑   Y↑   \-   PSMA7             \-     \-   \-   Y↓   \-   \-   \-       \-
  COMT              \-     \-   \-   \-                \-   Y↓   \-   \-   PTGFR             PM     \-   \-   \-   \-   \-   \-       \-
  CUEDC2            \-     \-   \-   \-                \-   \-   \-   \-   QKI               \-     \-   \-   \-   \-   \-   \-       \-
  CXCR7             PM     Y↓   \-   \-                \-   \-   Y↑   Y↑   RAMP1             PM     \-   Y    Y↑   \-   \-   \-       \-
  DHRS7             PM     \-   \-   \-                \-   \-   Y↓   \-   RNF208            \-     \-   \-   \-   \-   \-   \-       \-
  EEF1A2            \-     Y↑   \-   Y↑                \-   \-   \-   \-   RPL11             \-     \-   \-   \-   \-   \-   Y↓       \-
  EEF2              \-     \-   \-   \-                \-   \-   \-   \-   RPL28             \-     \-   \-   \-   \-   \-   \-       \-
  ELOVL5            PM     Y    Y    Y↓                \-   \-   \-   \-   RPS11             \-     \-   \-   \-   \-   \-   Y↓       \-
  *ENDOD1*          S      Y↑   \-   \-                \-   \-   \-   \-   *RPS18*           \-     \-   \-   Y↑   \-   \-   \-       \-
  *ENO2*            PM     \-   \-   \-                \-   \-   \-   \-   *RPS3*            \-     \-   \-   \-   \-   \-   \-       \-
  ENSG00000210082   \-     \-   \-   \-                \-   \-   \-   \-   *S100A10*         PM     \-   \-   \-   \-   \-   \-       \-
  ENSG00000211459   \-     \-   \-   \-                \-   \-   \-   \-   *SBDS*            \-     \-   \-   \-   \-   Y↑   \-       \-
  *FGFRL1*          PM     \-   \-   \-                \-   \-   \-   \-   *SELENBP1*        \-     Y↓   \-   Y↓   \-   \-   \-       \-
  *FKBP10*          \-     \-   \-   \-                \-   \-   \-   \-   *SERINC5*         \-     \-   \-   \-   \-   \-   \-       \-
  *GALNT3*          \-     \-   \-   Y↑                \-   Y↓   \-   \-   *SF3A2*           \-     \-   \-   \-   \-   \-   Y↑       \-
  GAS5              \-     \-   \-   \-                \-   \-   \-   \-   SFRS2B            \-     \-   \-   \-   \-   \-   \-       \-
  GLO1              \-     \-   \-   Y↑                Y↑   Y↑   \-   \-   SH3BP5L           \-     \-   \-   \-   \-   \-   \-       \-
  GNB2L1            PM     \-   \-   \-                \-   \-   Y↑   \-   SLC25A4           \-     \-   \-   Y↑   \-   \-   \-       \-
  GRB10             PM     \-   \-   \-                \-   \-   \-   \-   SLC25A6           \-     \-   \-   Y↑   \-   \-   \-       \-
  H2AFJ             \-     \-   \-   \-                \-   \-   \-   \-   SNX3              \-     \-   \-   \-   Y↑   \-   \-       \-
  HES6              \-     \-   \-   \-                \-   \-   Y↑   Y↑   *SPIRE1*          \-     \-   \-   \-   \-   \-   \-       \-
  *HLA-B*           PM     \-   \-   \-                \-   \-   \-   \-   *SPON2*           S      \-   Y    Y↑   \-   \-   \-       \-
  *HMGB2*           \-     \-   \-   \-                \-   \-   \-   Y↑   *STEAP1*          PM     \-   Y    Y↑   \-   \-   \-       \-
  *HN1*             \-     \-   \-   \-                \-   \-   Y↑   \-   *SYNC1*           \-     \-   \-   \-   \-   \-   \-       \-
  *HSD17B4*         \-     Y↑   \-   Y↑                \-   \-   \-   \-   *TFPI*            S      \-   \-   \-   \-   \-   \-       \-
  LOC644844         \-     \-   \-   \-                \-   \-   \-   \-   *TK1*             \-     \-   \-   \-   \-   \-   Y↑       \-
  *MAOA*            \-     Y    \-   \-                Y↑   \-   \-   \-   *TKT*             \-     \-   \-   \-   \-   \-   \-       \-
  *MARCKSL1*        PM     \-   \-   Y↑                \-   \-   \-   \-   *TMEM30A*         S&PM   \-   \-   \-   \-   Y↑   \-       \-
  *MDK*             S&PM   Y↓   \-   Y↑                \-   \-   \-   Y↑   *TMEM66*          S&PM   Y↑   \-   \-   \-   \-   \-       \-
  *MT-CO3*          \-     \-   \-   \-                \-   \-   \-   \-   *TPD52*           \-     Y↑   Y    Y↑   \-   Y↑   Y↓       \-
  *MT-ND3*          \-     \-   \-   \-                \-   \-   \-   \-   *TRPM8*           PM     Y↑   \-   Y↑   \-   \-   \-       Y↓
  *NAAA*            \-     \-   \-   \-                \-   \-   \-   Y↑   *UTX*             \-     \-   \-   \-   \-   \-   \-       \-
  *NAT14*           PM     \-   \-   \-                \-   \-   \-   \-   *VPS13B*          PM     \-   \-   \-   \-   \-   Y↑       \-
  *NELF*            PM     \-   \-   \-                \-   \-   \-   \-   *WDR45L*          \-     \-   \-   \-   \-   \-   \-       \-
  *NGFRAP1*         \-     \-   \-   Y↓                \-   \-   \-   \-   *YWHAQ*           \-     \-   \-   \-   \-   \-   \-       \-

\* Human Genome Nomenclature Committee (HGNC)-approved gene names were used when possible. Non-HGNC-approved gene names were not italicized.

† S or PM, gene product is thought to be secreted (S) or localize to the plasma membrane (PM)

‡ Reg. by A, gene expression changes in response to androgen in prostate cells

§ Spec. to P, gene expression is specific to- or enriched in- prostate tissue compared to other tissues

II CaP, gene is differentially expressed in prostate cancer compared to normal, benign prostatic hyperplasia, or prostatic intraepithelial neoplasia

¶ GG, gene is differentially expressed in higher Gleason grade tissue versus lower Gleason grade tissue

\*\* Prog., gene expression correlates with late-stage prostate cancer or is a risk factor that predicts progression

†† Mets, gene expression is associated with prostate cancer metastasis in human samples or *in vivo*models

‡‡ CR, gene is associated with castration-recurrent prostate cancer in human tissue or *in vivo*models, but exhibits an opposite trend of this report

§§ Y, yes; ↑, high gene expression; ↓, low gene expression

Novel CR-associated genes identify both clinical samples of CRPC and clinical metastasis of prostate cancer
-----------------------------------------------------------------------------------------------------------

The expression of novel CR-associated genes were validated in publically available, independent sample sets representing different stages of prostate cancer progression (Gene Expression Omnibus accession numbers: GDS1390 and GDS1439). Dataset GDS1390 includes expression data of ten AS prostate tissues, and ten CRPC tissues from Affymetrix U133A arrays \[[@B47]\]. Dataset GDS1439 includes expression data of six benign prostate tissues, seven localized prostate cancer tissues, and seven metastatic prostate cancer tissues from Affymetrix U133 2.0 arrays \[[@B97]\].

Unsupervised principal component analysis based on the largest three principal components revealed separate clustering of tumor samples representing AS and CR stages of cancer progression, with the exception of two CR samples and one AS sample (Figure [4a](#F4){ref-type="fig"}).

![**Principle component analyses of clinical samples**. *A*, Principle component analysis based on the expression of novel CR-associated genes in the downloaded dataset GDS1390 clustered the AS and CR clinical samples into two groups. *B*, Principle component analysis based on the expression of novel CR-associated genes in the downloaded dataset GDS1439 clustered the clinical samples (benign prostate tissue, benign; localized prostate cancer, Loc CaP; and metastatic prostate cancer, Met CaP) into three groups.](1755-8794-3-43-4){#F4}

Metastatic prostate cancer is expected to have a more progressive phenotype and is associated with hormonal progression. Therefore, the gene expression signature obtained from the study of hormonal progression may be common to that observed in clinical metastases. Unsupervised principal component analysis based on the largest three principal components revealed separate clustering of not only benign and malignant, but also localized and metastatic tissue samples (Figure [4b](#F4){ref-type="fig"}).

Discussion
==========

Genes that change levels of expression during hormonal progression may be indicative of the mechanisms involved in CRPC. Here we provide the most comprehensive gene expression analysis to date of prostate cancer with approximately 3 million long tags sequenced using *in vivo*samples of biological replicates at various stages of hormonal progression to improve over the previous libraries that are approximately 70,000 short tags or less. Previous large-scale gene expression analyses have been performed with tissue samples from men with advanced prostate cancer \[[@B42]-[@B58]\], and animal or xenograft models of CRPC \[[@B59]-[@B69]\]. Most of these previous studies compared differential expression between CRPC samples with the primary samples obtained before androgen ablation. This experimental design cannot distinguish changes in gene expression that are a direct response to androgen ablation, or from changes in proliferation/survival that have been obtained as the prostate cancer cells progress to more a more advanced phenotype. Here we are the first to apply an *in vivo*model of hormonal progression to compare gene expression between serial samples of prostate cancer before (AS), and after androgen ablation therapy (RAD) as well as when the cells become CR. This model is the LNCaP Hollow Fiber model \[[@B21]\] which has genomic similarity with clinical prostate cancer \[[@B23]\] and mimics the hormonal progression observed clinically in response to host castration as measured by levels of expression of PSA and cell proliferation. Immediately prior to castration, when the cells are AS, PSA levels are elevated and the LNCaP cells proliferate. A few days following castration, when the cells are RAD, PSA levels drop and the LNCaP cells cease to proliferate, but do not apoptose in this model. Approximately 10 weeks following castration, when the cells are CR, PSA levels rise and the LNCaP cells proliferate in the absence of androgen. This model overcomes some limitations in other studies using xenografts that include host contamination of prostate cancer cells. The hollow fibers prevent infiltration of host cells into the fiber thereby allowing retrieval of pure populations of prostate cells from within the fiber. The other important benefit of the fiber model is the ability to examine progression of cells to CRPC at various stages within the same host mouse over time, because the retrieval of a subset of fibers entails only minor surgery. The power to evaluate progression using serial samples from the same mouse minimizes biological variation to enhance the gene expression analyses. However, limitations of this model include the lack of cell-cell contact with stroma cells, and lack of heterogeneity in tumors. Typically, these features would allow paracrine interactions as expected in clinical situations. Consistent with the reported clinical relevance of this model \[[@B23]\], here principal component analysis based on the expression of these novel genes identified by LongSAGE, clustered the clinical samples of CRPC separately from the androgen-dependent samples. Principal component analysis based on the expression of these genes also revealed separate clustering of the different stages of tumor samples and also showed separate clustering of the benign samples from the prostate cancer samples. Therefore, some common changes in gene expression profile may lead to the survival and proliferation of prostate cancer and contribute to both distant metastasis and hormonal progression. We used this LNCaP atlas to identify changes in gene expression that may provide clues of underlying mechanisms resulting in CRPC. Suggested models of CRPC involve: the AR; steroid synthesis and metabolism; neuroendocrine prostate cancer cells; and/or an imbalance of cell growth and cell death.

Androgen receptor (AR)
----------------------

### Transcriptional activity of AR

The AR is suspected to continue to play an important role in the hormonal progression of prostate cancer. The AR is a ligand-activated transcription factor with its activity altered by changes in its level of expression or by interactions with other proteins. Here, we identified changes in expression of some known or suspected modifier of transcriptional activity of the ARin CRPC versus RAD such as Cyclin H (*CCNH*) \[[@B107]\], proteasome macropain subunit alpha type 7 (*PSMA7*) \[[@B108]\], CUE-domain-containing-2 (*CUEDC2*) \[[@B109]\], filamin A (*FLNA*) \[[@B110]\], and high mobility group box 2 (*HMGB2*) \[[@B111]\]. *CCNH*and *PSMA7*displayed increased levels of expression, while *CUEDC2, FLNA*, and *HMGB2*displayed decreased levels of expression in CR. The expression trends of *CCNH, CUEDC2, FLNA*, and *PSMA7*in CRPC may result in increased AR signaling through mechanisms involving protein-protein interactions or altering levels of expression of AR. CCNH protein is a component of the cyclin-dependent activating kinase (CAK). CAK interacts with the AR and increases its transcriptional activity \[[@B107]\]. Over-expression of the proteosome subunit PSMA7 promotes AR transactivation of a PSA-luciferase reporter \[[@B108]\]. A fragment of the protein product of *FLNA*negatively regulates transcription by AR through a physical interaction with the hinge region \[[@B110]\]. CUEDC2 protein promotes the degradation of progesterone and estrogen receptors \[[@B109]\]. These steroid receptors are highly related to the AR, indicating a possible role for CUEDC2 in AR degradation. Thus decreased expression of *FLNA*or *CUEDC2*could result in increased activity of the AR. Decreased expression of *HMGB2*in CRPC is predicted to decrease expression of at least a subset of androgen-regulated genes that contain palindromic AREs \[[@B111]\]. Here, genes known to be regulated by androgen were enriched in expression trend categories with a peak or valley at the RAD stage of prostate cancer progression. Specifically, 8 of the 13 tags (62%) exhibiting these expression trends \'E\', \'F\', \'J\', \'K\', or \'L\' represented known androgen-regulated genes, in contrast to only 22 of the remaining 122 tags (18%; Tables [4](#T4){ref-type="table"} &[5](#T5){ref-type="table"}). Overall, this data supports increased AR activity in CRPC, which is consistent with re-expression of androgen-regulated genes as previously reported \[[@B68]\] and similarity of expression of androgen regulated genes between CRPC and prostate cancer before androgen ablation \[[@B23]\].

### Steroid synthesis and metabolism

In addition to changes in expression of AR or interacting proteins altering the transcriptional activity of the AR, recent suggestion of sufficient levels of residual androgen in CRPC provides support for an active ligand-bound receptor \[[@B112]\]. The AR may become re-activated in CRPC due to the presence of androgen that may be synthesized by the prostate *de novo*\[[@B4]\] or through the conversion of adrenal androgens. Here, the expression of 5 genes known to function in steroid synthesis or metabolism were significantly differentially expressed in CRPC versus RAD. They are 24-dehydrocholesterol reductase (*DHCR24*) \[[@B113]\], dehydrogenase/reductase SDR-family member 7 (*DHRS7*) \[[@B114]\], elongation of long chain fatty acids family member 5 (*ELOVL5*) \[[@B115],[@B116]\], hydroxysteroid (17-beta) dehydrogenase 4 (*HSD17B4*) \[[@B117]\], and opioid receptor kappa 1 (*OPRK1*) \[[@B118]\]. Increased levels of expression of these genes may be indicative of the influence of adrenal androgens, or the local synthesis of androgen, to reactivate the AR to promote the progression of prostate cancer in the absence of testicular androgens.

Neuroendocrine
--------------

Androgen-deprivation induces neuroendocrine differentiation of prostate cancer. Here, the expression of 8 genes that are associated with neuroendocrine cells were significantly differentially expressed in CRPC versus RAD. They either responded to androgen ablation such as hairy and enhancer of split 6 (*HES6*) \[[@B119]\], karyopherin/importin beta 1 (*KPNB1*) \[[@B120]\], monoamine oxidase A (*MAOA*)\[[@B121]\], and receptor (calcitonin) activity modifying protein 1 (*RAMP1*) \[[@B122]\]\], or were increased expressed in CRPC such as *ENO2*\[[@B122]\], *OPRK1*\[[@B118]\], S100 calcium binding protein A10 (*S100A10*) \[[@B123]\], and transient receptor potential cation channel subfamily M member 8 (*TRPM8*) \[[@B124]\].

Proliferation and Cell survival
-------------------------------

The gene expression trends of *GAS5*\[[@B125]\], *GNB2L1*\[[@B126]\], *MT-ND3, NKX3-1*\[[@B127]\], *PCGEM1*\[[@B128]\], *PTGFR*\[[@B129]\], *STEAP1*\[[@B130]\], and *TMEM30A*\[[@B131]\] were in agreement with the presence of proliferating cells in CRPC. Of particular interest is that we observed a transcript anti-sense to *NKX3-1*, a tumor suppressor, highly expressed in the stages of cancer progression that were AS and CR, but not RAD. Anti-sense transcription may hinder gene expression from the opposing strand, and therefore, represents a novel mechanism by which *NKX3-1*expression may be silenced. There were also some inconsistencies including the expression trends of *BTG1*\[[@B132]\], *FGFRL1*\[[@B133]\], and PCOTH \[[@B134]\] and that may be associated with non-cycling cells. Overall, there was more support at the transcriptome level for proliferation than not, which was consistent with increased proliferation observed in the LNCaP Hollow Fiber model \[[@B21]\].

Gene expression trends of *GLO1*\[[@B135]\], *S100A10*\[[@B136]\], *TRPM8*\[[@B137]\], and *PI3KCD*\[[@B138]\] suggest cell survival pathways are active following androgen-deprivation and/or in CRPC, while gene expression trends of *CAMK2N1*\[[@B139]\], *CCT2*\[[@B140]\], *MDK*\[[@B141],[@B142]\], *TMEM66*\[[@B143]\], and *YWHAQ*\[[@B136]\] may oppose such suggestion. Taken together, these data neither agree nor disagree with the activation of survival pathways in CRPC. In contrast to earlier reports in which *MDK*gene and protein expression was determined to be higher in late stage cancer \[[@B63],[@B142]\], we observed a drop in the levels of *MDK*mRNA in CRPC versus RAD. *MDK*expression is negatively regulated by androgen \[[@B65]\]. Therefore, the decreased levels of *MDK*mRNA in CRPC may suggest that the AR is reactivated in CRPC.

Other
-----

The significance of the gene expression trends of *AMD1, BNIP3, GRB10, MARCKSL1*, *NGRAP1, ODC1, PPP2CB, PPP2R1A, SLC25A4, SLC25A6*, and *WDR45L*that function in cell growth or cell death/survival were not straightforward. For example, *BNIP3*and *WDR45L*, both relatively highly expressed in CRPC versus RAD, may be associated with autophagy. BNIP3 promotes autophagy in response to hypoxia \[[@B144]\], and the WDR45L-related protein, WIPI-49, co-localizes with the autophagic marker LC3 following amino acid depletion in autophagosomes \[[@B145]\]. It is not known if BNIP3 or putative WDR45L-associated autophagy results in cell survival or death. Levels of expression of *NGFRAP1*were increased in CRPC versus RAD. The protein product of *NGFRAP1*interacts with p75 (NTR). Together they process caspase 2 and caspase 3 to active forms, and promote apoptosis in 293T cells \[[@B146]\]. NGFRAP1 requires p75 (NTR) to induce apoptosis. However, LNCaP cells do not express p75 (NTR), and so it is not clear if apoptosis would occur in this cell line \[[@B147]\].

Overall, genes involved in cell growth and cell death pathways were altered in CRPC. Increased tumor burden may develop from a small tip in the balance when cell growth outweighs cell death. Unfortunately, the contributing weight of each gene is not known, making predictions difficult based on gene expression alone of whether proliferation and survival were represented more than cell death in this model of CRPC. It should be noted that LNCaP cells are androgen-sensitive and do not undergo apoptosis in the absence of androgens. The proliferation of these cells tends to decrease in androgen-deprived conditions, but eventually with progression begins to grow again mimicking clinical CRPC.

Conclusion
==========

Here, we describe the LNCaP atlas, a compilation of LongSAGE libraries that catalogue the transcriptome of human prostate cancer cells as they progress to CRPC *in vivo*. Using the LNCaP atlas, we identified differential expression of 96 genes that were associated with castration-recurrence *in vivo*. These changes in gene expression were consistent with the suggested model for a role of the AR, steroid synthesis and metabolism, neuroendocrine cells, and increased proliferation in CRPC.
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*ACPP*: prostate acid phosphatise; ACTH: adrenocorticotropic hormone; AR: androgen receptor; AREs: androgen response elements; AS: androgen-sensitive; *BAX*: BCL2-associated X protein; *BCL-2*: B-cell CLL/lymphoma 2; *BCL2L1*: BCL2-like 1; CAK: cyclin-dependent activating kinase; *CCND1*: cyclin D1; CCNH: Cyclin H; *CDKN1A*: cyclin-dependent kinase inhibitor 1A; *CDKN1B*: cyclin-dependent kinase inhibitor 1B; *CHG*: chromogranin; CR: castration-recurrent; CRPC: castration-recurrent prostate cancer; CUEDC2: CUE-domain-containing-2; DHCR24: 24-dehydrocholesterol reductase; DHRS7: dehydrogenase/reductase SDR-family member 7; EASE: Expression Analysis Systematic Explorer; ELOVL5: elongation of long chain fatty acids family member 5; ENO2: neuronal enolase 2; FLNA: filamin A; GO: Gene Ontology; HES6: hairy and enhancer of split 6; HGNC: HUGO Gene Nomenclature Committee; HMGB2: high mobility group box 2; *HMGCS1*: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1; HPA: hypothalamus-pituitary-adrenal; *HSD17B3*: hydroxysteroid (17-beta) dehydrogenase 3; HSD17B4: hydroxysteroid (17-beta) dehydrogenase 4; *HSD17B5*: hydroxysteroid (17-beta) dehydrogenase 5; IL6: interleukin 6; KEGG: Kyoto Encyclopedia of Genes and Genomes; *KLK3*: kallikrein 3; KPNB1: karyopherin/importin beta 1; LHRH: Leutinizing hormone releasing hormone; LongSAGE: long serial analysis of gene expression; MAOA: monoamine oxidase A; *NCOA*: nuclear receptor coactivator; *NKX3-1*: NK3 homeobox 1; *NTS*: neurotensin; OPRK1: opioid receptor kappa 1; PKA: protein kinase A; PSA: prostate-specific antigen also known as KLK3; PSMA7: proteasome macropain subunit alpha type 7; PTHrP: parathyroid hormone-related protein; qRT-PCR: quantitative real time-polymerase chain reaction; RAD: responsive to androgen-deprivation; RAMP1: receptor (calicitonin) activity modifying protein 1; *RB1*: retinoblastoma 1; S100A10: S100 calcium binding protein A10; *SQLE*: squalene epoxidase; TRPM8: transient receptor potential cation channel subfamily M member 8.
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###### Additional file 1

**Supplementary Figures**. **Figure S1**: qRT-PCR analysis of *KLK3*gene expression during hormonal progression of prostate cancer to castration-recurrence. RNA samples were retrieved from the *in vivo*LNCaP Hollow Fiber model at different stages of cancer progression that were: AS, androgen-sensitive, day zero (just prior to surgical castration and 7 days post-fiber implantation); RAD, responsive to androgen-deprivation, 10 days post-surgical castration; and CR, castration-recurrent, 72 days post-surgical castration. MNE, mean normalized expression, calculated by normalization to glyceraldehyde-3-phosphate (*GAPDH*). Error bars represent ± standard deviation of technical triplicates. Each mouse represents one biological replicate. **Figure S2**: Ten K-means clusters are optimal to describe the expression trends present during progression to castration-recurrence. K-means clustering was conducted over a range of K (number of clusters) from K = 2 to K = 20 and the within-cluster dispersion was computed for each clustering run and plotted against K. The within-cluster dispersion declined with the addition of clusters and this decline was most pronounced at K = 10. The graph of within cluster dispersion versus K shown here is for mouse 13N, but the results were similar for mice 15N and 13R. **Figure S3**: Trend legend for Table [4](#T4){ref-type="table"}. Gene expression trends of LongSAGE tags that consistently and significantly altered expression in CR prostate cancer are represented graphically with trends labeled A-P. \* Statistics according to the Audic and Claverie test statistic (p ≤ 0.05).
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